Cargando…

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study

BACKGROUND: Effective adjuvant therapy for osteosarcoma is necessary for improved outcomes. Previous studies demonstrated that apatinib plus doxorubicin-based chemotherapy may improve the efficacy of neoadjuvant therapy. This study aimed to clarify the effectiveness and safety of apatinib plus doxor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiaqiang, Zhang, Fan, Dong, Shuping, Yang, Yang, Gao, Fangfang, Liu, Guancong, Zhang, Peng, Wang, Xin, Du, Xinhui, Tian, Zhichao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679406/ https://www.ncbi.nlm.nih.gov/pubmed/38023239 http://dx.doi.org/10.3389/fonc.2023.1227461

Ejemplares similares

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study
por: Tian, Zhichao, et al.
Publicado: (2020)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis
por: Tian, Zhichao, et al.
Publicado: (2020)

Argon-helium knife cryoablation plus programmed cell death protein 1 inhibitor in the treatment of advanced soft tissue sarcomas: there is no evidence of the synergistic effects of this combination therapy
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
por: Tian, Zhichao, et al.
Publicado: (2019)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review
por: Zhang, Mengxi, et al.
Publicado: (2019)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience
por: Xie, Lu, et al.
Publicado: (2021)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

Osteosarcoma Cell-Derived Exosomal ELFN1-AS1 Mediates Macrophage M2 Polarization via Sponging miR-138-5p and miR-1291 to Promote the Tumorgenesis of Osteosarcoma
por: Wang, Bangmin, et al.
Publicado: (2022)

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
por: Wang, Jijin, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities
por: Du, Xinhui, et al.
Publicado: (2023)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
por: Li, Ning, et al.
Publicado: (2021)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

A case report of apatinib in treating osteosarcoma with pulmonary metastases
por: Zhou, Yong, et al.
Publicado: (2017)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
por: Yang, Zhi-Ran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o135jaq3d16o3d9ghcvovm524n